Gabrail Cancer Center gets FDA green light for elranatamab and STAR-LLD myeloma study

Gabrail Cancer Center said the FDA has cleared an investigator-initiated trial of STAR-LLD plus elranatamab in relapsed or refractory multiple myeloma. The study will test whether controlled low-dose lenalidomide can improve response durability while limiting blood-related toxicity, with enrollment expected to start in Q4 2026.

Why it matters: - The study is designed to address two common limits of T-cell engager therapy in multiple myeloma: eventual resistance and hematologic toxicity from combination regimens. - If the approach works, it could help more patients stay on treatment longer and may make bispecific therapy easier to use in community oncology settings. - The trial also targets a real-world treatment gap: many multiple myeloma patients receive care outside academic centers.

What happened: - Gabrail Cancer and Research Center said the U.S. Food and Drug Administration notified Nashat Gabrail, M.D., that the investigator-initiated trial may proceed under his Investigational New Drug application. - The study will evaluate STAR-LLD in combination with elranatamab in patients with relapsed or refractory multiple myeloma. - Enrollment is expected to begin in Q4 2026.

The details: - The trial will assess dose-finding, safety and preliminary efficacy. - The study will test controlled low-dose delivery of lenalidomide, designed to maintain sustained exposure to the drug’s immunomodulatory activity. - The goal is to avoid the high peak concentrations associated with conventional oral dosing. - The research builds on evidence that immunomodulatory drugs and CELMoDs can enhance T-cell engager therapy. - The combination is intended to improve response depth and durability while lowering hematologic toxicity. - Standard oral lenalidomide combinations with T-cell engagers can raise the risk of blood-related toxicity and infection. - Those side effects can force dose reductions, treatment interruptions and discontinuations. - T-cell engager therapies, including BCMA-directed bispecific antibodies such as elranatamab, are increasingly important in multiple myeloma and lymphoma. - Unlike CAR-T cell therapies, T-cell engagers can be administered in community oncology settings under controlled conditions.

Between the lines: - The trial reflects a broader effort to preserve the immune benefits of lenalidomide while reducing the toxicity that can undermine combination treatment. - Nashat Gabrail said the study is meant to test whether STAR-LLD’s controlled delivery profile can preserve or potentially improve efficacy while reducing hematologic toxicity and extending response duration. - Carrie Smith, RN, chief operations officer of the research division, said the community oncology setting makes the study more representative of everyday multiple myeloma care in the United States.

What's next: - Gabrail Cancer Center plans to begin enrolling patients in Q4 2026. - The trial will generate early data on safety, dosing and whether the combination can improve clinical activity. - The center said the results will help evaluate whether the regimen can better balance efficacy and toxicity in routine practice.

The bottom line: - Gabrail Cancer Center is betting that a low-dose lenalidomide strategy can make elranatamab more durable without adding the toxicity that often limits standard combinations. - More information is available at the center's website and its LinkedIn page.